PE-22-28

Cognitive & Nootropic

🧠

PE-22-28

Spadin fragment · TREK-1 blocker peptide

PreclinicalCognitive & Nootropic🧠 Nootropics Hub

Synthetic octapeptide fragment of spadin that blocks TREK-1 potassium channels, producing rapid antidepressant and cognitive effects in preclinical models.

Half-Life

~1–2 hours (estimated, short due to peptidase degradation)

MW

950.1 Da

Amino Acids

8 AA

Evidence

Preclinical

Regulatory Status

Research compound. No clinical trials or regulatory approval.

In Plain English

A short peptide that blocks a brain potassium channel (TREK-1) linked to depression and poor cognition. In animal studies it produces fast antidepressant effects — within hours rather than the weeks needed for SSRIs. Still in preclinical stages with no human data.

Overview

PE-22-28 is a synthetic 8-amino acid C-terminal fragment of spadin, itself a fragment of the natriuretic peptide proBNP. It selectively blocks TREK-1 (TWIK-related potassium channel 1), a two-pore domain potassium channel linked to depression, stress, and cognitive function. In rodent models, PE-22-28 produces rapid antidepressant-like effects comparable to or faster than conventional antidepressants, with onset within hours rather than weeks. It has also been studied for effects on hippocampal neurogenesis and memory.

Common Formats

  • Injectable (subcutaneous)
  • Intranasal

Storage Notes

Store at -20°C lyophilized. Reconstituted solution stable up to 2 weeks refrigerated. Sensitive to repeated freeze-thaw cycles.

Looking for multi-compound protocols?

Browse educational protocol discussions that include PE-22-28.

Protocol Library

Research Sources

(3 vendors)

For research use only. No affiliation or endorsement implied.

Related Compounds

Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.